Amy E DeZern

15PUBLICATIONS
107CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Gene and molecular therapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 07, 2026
Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Feb 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesis.

Sadegh Marzban, Thomas Stiehl, Zhuoer Xie

|Feb 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur

|Dec 03, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.

Carmelo Gurnari, Hideki Makishima, Arda Durmaz

Pageof 3

Frequent Collaborators

4 joint publications

Alexander J Ambinder

3 joint publications

Zhuoer Xie

3 joint publications

Lukasz P Gondek

3 joint publications

Theodoros Karantanos